WO2016029125A8 - Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer - Google Patents

Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer Download PDF

Info

Publication number
WO2016029125A8
WO2016029125A8 PCT/US2015/046314 US2015046314W WO2016029125A8 WO 2016029125 A8 WO2016029125 A8 WO 2016029125A8 US 2015046314 W US2015046314 W US 2015046314W WO 2016029125 A8 WO2016029125 A8 WO 2016029125A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
seq
methods
peptide reagents
targeting
Prior art date
Application number
PCT/US2015/046314
Other languages
French (fr)
Other versions
WO2016029125A1 (en
Inventor
Thomas D. Wang
Juan Zhou
Bishnu P. JOSHI
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Priority to US15/505,846 priority Critical patent/US10500290B2/en
Priority to CN201580050594.XA priority patent/CN107073065B/en
Publication of WO2016029125A1 publication Critical patent/WO2016029125A1/en
Publication of WO2016029125A8 publication Critical patent/WO2016029125A8/en
Priority to US16/708,244 priority patent/US20200102349A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).
PCT/US2015/046314 2014-08-22 2015-08-21 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer WO2016029125A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/505,846 US10500290B2 (en) 2014-08-22 2015-08-21 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
CN201580050594.XA CN107073065B (en) 2014-08-22 2015-08-21 Peptide reagents and methods for detection and targeting of dysplasia, early stage cancer and cancer
US16/708,244 US20200102349A1 (en) 2014-08-22 2019-12-09 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040590P 2014-08-22 2014-08-22
US62/040,590 2014-08-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/505,846 A-371-Of-International US10500290B2 (en) 2014-08-22 2015-08-21 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
US16/708,244 Continuation-In-Part US20200102349A1 (en) 2014-08-22 2019-12-09 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

Publications (2)

Publication Number Publication Date
WO2016029125A1 WO2016029125A1 (en) 2016-02-25
WO2016029125A8 true WO2016029125A8 (en) 2016-05-19

Family

ID=55351295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/046314 WO2016029125A1 (en) 2014-08-22 2015-08-21 Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

Country Status (3)

Country Link
US (1) US10500290B2 (en)
CN (1) CN107073065B (en)
WO (1) WO2016029125A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11235066B2 (en) 2015-12-02 2022-02-01 The Regents Of The University Of Michigan Micelles and methods
CN107446016A (en) * 2016-05-30 2017-12-08 上海交通大学 A kind of cell-penetrating peptide of Stearate Modified and its preparation and application
US20210253639A1 (en) * 2018-05-16 2021-08-19 Regents Of The University Of Michigan Heterodimeric peptide reagents and methods
CN109265519B (en) * 2018-10-23 2021-08-06 饶本强 Targeting fragment taking 3 tissue factors as targets
US20220193271A1 (en) * 2019-02-21 2022-06-23 The Regents Of The University Of Michigan Detection of colonic neoplasia in vivo using near-infrared peptide targeted against overexpressed cmet

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012558A1 (en) * 1997-09-10 1999-03-18 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
CA2361621A1 (en) * 1999-01-27 2000-08-03 Richard Jove Inhibition of stat3 signal transduction for human cancer therapy
US20050019826A1 (en) * 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
EP1364201A4 (en) * 2001-02-06 2005-01-05 Univ Auburn DEVICES FOR DETECTING LIGANDS AND USE THEREOF
WO2003037172A2 (en) * 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
NZ582521A (en) * 2007-07-12 2011-09-30 Prosensa Technologies Bv A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue
US8247529B2 (en) * 2008-05-19 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Neoplasia targeting peptides and methods of using the same
US8362203B2 (en) * 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
WO2010117997A2 (en) * 2009-04-07 2010-10-14 University Of Kansas Peptide targeting of inner ear cells
US20100260673A1 (en) 2009-04-10 2010-10-14 Qizhen Cao Phage display peptide probes for imaging early responses to antiangiogenic treatment
WO2010121266A1 (en) * 2009-04-18 2010-10-21 The Regents Of The University Of Michigan Targeted detection of dysplasia in barrett's esophagus with a novel fluorescence-labeled polypeptide
WO2011101696A1 (en) * 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
CA2797247C (en) * 2010-04-28 2019-10-22 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
EP2385057A1 (en) * 2010-05-05 2011-11-09 Centre National de la Recherche Scientifique Peptide derivatives for biofunctionalization of silicon substrates and their applications
US8901276B2 (en) * 2010-12-20 2014-12-02 The Regents Of The University Of Michigan Peptide reagents and methods for detection of colon dysplasia
WO2012123018A1 (en) * 2011-03-15 2012-09-20 Nanomed3D S.R.L. Functionalized biomaterials for tissue regeneration

Also Published As

Publication number Publication date
US10500290B2 (en) 2019-12-10
CN107073065B (en) 2021-07-02
CN107073065A (en) 2017-08-18
US20170246324A1 (en) 2017-08-31
WO2016029125A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
WO2015114506A3 (en) Biosensors for the detection of infection and associated maladies
AU2017260630A1 (en) Detection of lung neoplasia by analysis of methylated DNA
EP3156498A4 (en) Breast cancer detection kit or device, and method for detecting breast cancer
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
EP3159416A4 (en) Kit or device for detecting lung cancer, and lung cancer detection method
IN2014DN08695A (en)
EP3159406A4 (en) Esophageal cancer detection kit or device, and detection method
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
WO2015006555A3 (en) Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
MX2013000917A (en) Methods of detecting diseases or conditions using phagocytic cells.
WO2016029125A8 (en) Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
WO2018136919A3 (en) Methods relating to lung cancer
WO2015197874A3 (en) Combination of cd95/cd95l inhibition and cancer immunotherapy
EP3096784A4 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
EP4513187A3 (en) Methods of detecting prostate cancer
PH12019550180A1 (en) A methylation classifier for detection of hpv-induced invasive cancers, nonhpv-induced gynaecological and anogenital cancers and their high-grade precursor lesions
EP3693742A3 (en) Methods of detecting prostate cancer
EP3221701A4 (en) Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
GB201516975D0 (en) PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes
WO2013049398A3 (en) Protein-protein interaction as biomarkers
WO2016138245A3 (en) Claudin-1 peptide reagents and methods
WO2019012481A3 (en) Split g-quadruplexes for capture and detection of nucleic acids
WO2015107430A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2015120242A3 (en) Improved sensitivity for molecular detection of microbes in the bloodstream

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15834508

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15834508

Country of ref document: EP

Kind code of ref document: A1